Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.383 USD | +4.19% | +2.82% | -92.69% |
May. 07 | Jefferies Downgrades Lyra Therapeutics to Hold, Price Target at $0.50 | MT |
May. 07 | HC Wainwright Downgrades Lyra Therapeutics to Neutral From Buy | MT |
Chart calendar Lyra Therapeutics, Inc.
Upcoming events on Lyra Therapeutics, Inc.
Past events on Lyra Therapeutics, Inc.
2024-04-30 04:04 pm | Q1 2024 Earnings Release |
2024-03-21 04:01 pm | Q4 2023 Earnings Release |
2023-11-29 09:30 am | Piper Sandler Healthcare Conference |
2023-11-16 08:30 am | Jefferies London Healthcare Conference |
2023-11-07 04:01 pm | Q3 2023 Earnings Release |
2023-09-29 | American Rhinologic Society Meeting |
2023-09-26 02:45 pm | Cantor Global Healthcare Conference |
2023-09-13 02:00 pm | H.C. Wainwright Global Investment Conference |
2023-09-12 08:00 am | LYR-220 BEACON Phase 2 Clinical Study Results Call |
2023-08-08 04:01 pm | Q2 2023 Earnings Release |
2023-07-18 10:00 am | William Blair Virtual Biotechnology Conference |
2023-06-13 08:30 am | Annual General Meeting |
2023-06-07 10:30 am | Jefferies Global Healthcare Conference |
2023-05-12 07:00 am | Q1 2023 Earnings Release |
2023-05-10 07:35 pm | Bank of America Healthcare Conference |
2023-03-29 04:06 pm | Q4 2022 Earnings Release |
2022-11-17 11:25 am | Jefferies London Healthcare Conference |
2022-11-15 04:10 pm | Stifel Healthcare Conference |
2022-11-14 | Q3 2022 Earnings Release (Projected) |
2022-09-14 12:00 pm | H.C. Wainwright Global Investment Conference |
Annual results
Fiscal Period | December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
---|---|---|---|---|---|---|---|
Net sales Million USD | Released Forecast Spread | 0,00 | 0,00 0,00 - | 0,29 1,01 -71.76% | 1,36 4,84 -71.84% | 1,56 1,74 -10.41% | 1,57 |
EBITDA Million USD | Released Forecast Spread | 0,00 | -22,1 -19,6 -12.98% | -42,6 -41,8 -2.04% | -53,9 -52,8 -2.17% | 0,00 -73,3 - | -61,5 |
EBIT Million USD | Released Forecast Spread | 0,00 | -22,2 -22,1 -0.33% | -43,6 -40,7 -7.28% | -55,0 -53,4 -3.03% | -67,1 -68,9 2.53% | -86,0 |
Earnings before Tax (EBT) Million USD | Released Forecast Spread | 0,00 | -22,1 -21,2 -4.34% | -43,5 -39,9 -9.12% | -55,3 -54,5 -1.43% | -62,6 -65,1 3.85% | -82,7 |
Net income Million USD | Released Forecast Spread | 0,00 | -22,1 -21,9 -1.1% | -43,5 -40,6 -7.24% | -55,3 -53,3 -3.74% | -62,7 -65,2 3.8% | -82,8 |
EPS USD | Released Forecast Spread | -2,37 | -2,59 -2,01 -28.86% | -3,35 -3,12 -7.37% | -1,83 -1,78 -2.81% | -1,26 -1,31 3.69% | -1,21 |
Announcement Date | 06/03/20 | 09/03/21 | 09/03/22 | 29/03/23 | 21/03/24 | - |
Quarterly results
Fiscal Period | December | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net sales Million USD | Released Forecast Spread | 5,37 1,25 329.36% | 0,41 1,91 -78.72% | 0,36 0,14 164.61% | 0,01 0,19 -94.09% | 0,41 0,16 157.05% | 0,46 0,14 235.11% | 0,54 0,37 46.39% | 0,15 0,39 -62.45% | 0,53 0,35 53.83% | 0,36 | 0,36 | 0,33 | 0,00 | 0,00 |
EBITDA Million USD | Released Forecast Spread | -14,5 -13,1 -11.2% | -13,6 -15,0 9.38% | -21,4 | -20,7 | -9,60 | -9,00 | ||||||||
EBIT Million USD | Released Forecast Spread | -7,03 -13,3 47.09% | -14,5 -11,9 -22.16% | -14,8 -15,0 1.44% | -13,8 -15,1 8.46% | -17,3 -14,8 -16.66% | -16,5 -17,7 6.52% | -16,8 -16,6 -1.13% | -16,5 -18,7 12.12% | -23,5 -17,5 -34.11% | -22,8 | -20,4 | -19,5 | -9,50 | -7,50 |
Earnings before Tax (EBT) Million USD | Released Forecast Spread | -7,01 -12,6 44.53% | -14,5 -10,8 -33.51% | -14,8 -16,0 7.77% | -14,2 -15,0 5.34% | -16,2 -14,5 -12.21% | -15,6 -17,4 10.2% | -15,6 -16,0 2.56% | -15,1 -16,9 10.45% | -22,4 -16,9 -33.05% | -22,5 | -21,9 | -20,7 | -9,50 | -7,50 |
Net income Million USD | Released Forecast Spread | -7,01 -13,3 47.16% | -14,5 -11,9 -22.06% | -14,8 -15,0 1.75% | -14,2 -15,1 5.82% | -16,3 -14,5 -12.31% | -15,6 -17,4 10.13% | -15,7 -16,0 2.46% | -15,2 -18,2 16.63% | -22,5 -16,9 -33.1% | -22,0 | -19,7 | -18,8 | -9,50 | -7,50 |
EPS USD | Released Forecast Spread | -0,54 -0,92 40.98% | -0,43 -0,36 -19.44% | -0,40 -0,44 8.68% | -0,36 -0,41 13.04% | -0,44 -0,37 -20.55% | -0,36 -0,42 14.96% | -0,27 -0,32 15.09% | -0,19 -0,32 39.68% | -0,35 -0,27 -27.74% | -0,33 | -0,28 | -0,26 | -0,23 | -0,21 |
Announcement Date | 10/05/22 | 09/08/22 | 08/11/22 | 29/03/23 | 12/05/23 | 08/08/23 | 07/11/23 | 21/03/24 | 30/04/24 | - | - | - | - | - |
2024-05-20 | ALVOTECH: Q1 2024 Earnings Release |
2024-05-21 07:00 am | EXSCIENTIA PLC: Q1 2024 Earnings Release |
2024-05-21 | CUREVAC N.V.: Q1 2024 Earnings Release (Projected) |
2024-05-21 | EVOTEC SE: Q1 2024 Earnings Release |
2024-06-30 | IMMUNOVANT, INC.: Q4 2024 Earnings Release (Projected) |
2024-07-15 01:45 am | ADDLIFE AB: Q2 2024 Earnings Release |
2024-07-21 | MEDPACE HOLDINGS, INC.: Q2 2024 Earnings Release (Projected) |
2024-07-23 | SYNGENE INTERNATIONAL LIMITED: Q1 2025 Earnings Release (Projected) |
2024-07-23 | ALKERMES PLC: Q2 2024 Earnings Release (Projected) |
2024-07-23 | IQVIA HOLDINGS INC.: Q2 2024 Earnings Release (Projected) |
Past sector events for Lyra Therapeutics, Inc.
2024-05-17 02:00 am | BIOARCTIC AB: Q1 2024 Earnings Release |
2024-05-15 04:05 pm | CULLINAN THERAPEUTICS, INC.: Q1 2024 Earnings Release |
2024-05-14 | GNI GROUP LTD.: Q1 2024 Earnings Release |
2024-05-14 04:05 pm | NUVATION BIO INC.: Q1 2024 Earnings Release |
2024-05-14 07:30 am | ABSCI CORPORATION: Q1 2024 Earnings Release |
2024-05-14 01:50 am | BELITE BIO, INC: Q1 2024 Earnings Release |
2024-05-13 | POLARIS GROUP: Q1 2024 Earnings Release |
2024-05-13 04:30 pm | AEROVATE THERAPEUTICS, INC.: Q1 2024 Earnings Release |
2024-05-13 07:00 am | APOGEE THERAPEUTICS, INC.: Q1 2024 Earnings Release |
2024-05-12 07:00 pm | PRAXIS PRECISION MEDICINES, INC.: Q1 2024 Earnings Release |
Net sales - Quarter - Rate of surprise
Quarterly earnings - Rate of surprise
Net sales - Annual - Rate of surprise
Annual profits - Rate of surprise
- Stock Market
- Equities
- LYRA Stock
- Calendar Lyra Therapeutics, Inc.